Title: Effects of neoadjuvant chemotherapy in ovarian cancer patients with different germline BRCA1/2 mutational status

Abstract

Background: Whether neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) against primary debulking surgery (PDS) has a differential effect on prognosis due to Breast Cancer Susceptibility Genes (BRCA)1/2 mutations has not been confirmed by current studies. Methods: All patients included in this retrospective study were admitted to Qilu Hospital of Shandong University between January 2009 and June 2020, and germline BRCA1/2 mutation was tested. Patients in stage IIIB, IIIC, and IV, re-staged by International Federation of Gynecology and Obstetrics (FIGO) 2014, were selected for the analysis. All patients with NAC received 1-5 cycles of platinum-containing (carboplatin, cisplatin, or nedaplatin) chemotherapy. Patients who received maintenance therapy after chemotherapy were not eligible for this study. All relevant medical records were collected. Results: A total of 322 patients were enrolled, including 112 patients with BRCA1/2 mutations (BRCAmut), and 210 patients with BRCA1/2 wild-type (BRCAwt). In the two groups, 40 BRCAmut patients (35.7%) and 69 BRCAwt patients (32.9%) received NAC. Regardless of the BRCA1/2 mutational status,there were no statistical differences in NAC-IDS and PDS groups for progression-free survival (PFS)

Biography

Hualei Bu,MD;Attending physician of Qilu Hospital, Shandong University, China; Member of Chemotherapy and Clinical Trial Research Committee, Gynecological Oncology Branch, Shandong Anti-cancer Association, China. Bu has participated in more than ten international and domestic clinical trials of gynecological malignant tumors as a key Sub-I, including FZOCUS-1/2/3 studies of Fluzoparib for recurrent ovarian cancer and maintenance therapy, SOLO-1/SOLO-2/L-MOCA studies of Olaparib, NORA/PRIMA studies of Niraparib, and studies on the treatment of recurrent endometrial carcinoma and cervical cancer of PD-1/PD-L1 antibodies. As a clinician, Dr. Buhas rich clinical experience in surgical treatment, chemotherapy and targeted therapy of gynecological malignant tumors.